

Robert Greene Sterne  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Comwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Millonig  
Lawrence B. Bugaisky  
Donald J. Featherstone  
Michael V. Messinger

Judith U. Kim  
Timothy J. Shea, Jr.  
Patrick E. Garrett  
Jeffrey T. Helvey  
Heidi L. Kraus  
Crystal D. Sayles  
Edward W. Yee  
Albert L. Ferro  
Donald R. Banowitz  
Peter A. Jackman  
Molly A. McCall  
Teresa U. Medler  
Jeffrey S. Weaver  
Kendrick P. Patterson  
Vincent L. Capuano  
Albert J. Fasulo II  
Eldora Ellison Floyd  
W. Russell Swindell

Thomas C. Fiala  
Brian J. Del Buono  
Virgil Lee Beaston  
Reginald D. Lucas  
Kimberly N. Reddick  
Theodore A. Wood  
Elizabeth J. Haanes  
Bruce E. Chalker  
Joseph S. Ostroff  
Frank R. Cottingham  
Christine M. Lhullier  
Rae Lynn Pregarman  
Jane Shershenovich  
Lawrence J. Carroll  
George S. Bardmesser  
Daniel A. Klien  
Rodney G. Maze  
Jason D. Eisenberg  
Michael A. Specht

Registered Patent Agents  
Karen R. Markowicz  
Andrea J. Kamage  
Nancy J. Leith  
Ann E. Summerfield  
Helene C. Carlson  
Gabby L. Longworth  
Matthew J. Dowd  
Aaron L. Schwartz  
Angelique G. Uy  
Boris A. Matvenko  
Mary B. Tung  
Katrina Y. Pei  
Bryan L. Skelton  
Robert A. Schwartzman  
John J. Figueroa  
Timothy A. Doyle  
Jennifer R. Mahalingappa

Senior Counsel  
Samuel L. Fox  
Kenneth C. Bass III  
Lisa A. Dunner

TECH 0  
0200  
PM 4: 18  
RECEIVED  
OCT 31 2002  
WRITER'S DIRECT NUMBER  
(202) 371-2568  
INTERNET ADDRESS:  
RESMOND@SKGF.COM

October 29, 2002

**RECEIVED**

OCT 31 2002

TECH CENTER 1600/2900

Commissioner for Patents  
Washington, D.C. 20231

Via Hand-Carry to  
Examiner N.T. Nashed  
Art Unit 1652

Re: U.S. Utility Patent Application Patent Application  
Appl. No. 09/064,057; Filed: April 22, 1998  
For: **Compositions and Methods for Reverse Transcription of Nucleic Acid  
Molecules**  
Inventors: Gerard *et al.*  
Our Ref: 094.4330002/RWE/MTT

Sir:

Transmitted herewith for appropriate action are the following documents:

1. A courtesy copy of the Ninth Supplemental Information Disclosure Statement, Form PTO-1449 (1 sheet) and postcard receipt filed on February 20, 2002;
2. A courtesy copy of the following documents, submitted on February 20, 2002: **AR25 and AS25**; and
3. One (1) Return Postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents  
October 29, 2002  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, reading "Robert W. Esmond". The signature is written in a cursive style with a large, looped "R" and "E".

Robert W. Esmond  
Attorney for Applicants  
Registration No. 32,893

RWE/MTT/dnk  
Enclosures

ODMAMHODMASKGF\_DC1;69225;1  
SKGF Rev. 2/15/02 dcw

RECEIVED  
TECH CENTER 1600/2900

02 OCT 29 PM 4: 18

**Applicant:** Gerard *et al.*

**Application No.:** 09/064,057

**Filed:** April 22, 1998

**For:** Compositions and Methods for Reverse Transcription of Nucleic Acid Molecules

**Due Date:** March 15, 2002

**Art Unit:** 1652

**Examiner:** Monshipouri, M.

**Docket:** 0942.4330002

**Atty:** RWE/MTT

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. SKGF Cover Letter;
2. Petition for Extension of Time Under 37 C.F.R. §1.136(a)(1);
3. Fee Transmittal Form PTO/SB/17;
4. Request for Continued Examination Transmittal (Form PTO/SB/30);
5. Preliminary Amendment;
6. Ninth Supplemental Information Disclosure Statement;
7. List of cited references on Form PTO-1449;
8. A copy of each reference cited on Form PTO-1449;
9. Check no. 34242 in the amount of \$1140.00 to cover:
  - \$400.00 Extension of time; and
  - \$740.00 RCE fee; and
  - \$180.00 extra claims fee; and
10. Return Postcard.



Please Date Stamp And Return To Our Courier

RECEIVED  
OCT 31 2002  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GERARD *et al.*

Appl. No. 09/064,057

Filed: April 22, 1998

For: **Compositions and Methods for  
Reverse Transcription of Nucleic  
Acid Molecules**

Art Unit: 1652

Examiner: Monshipouri, M.

Atty. Docket: 0942.4330002/RWE/MTT

RECEIVED  
TECH CENTER 1600/2900  
OCT 29 PM 4:11

**Ninth Supplemental Information Disclosure Statement**

Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

OCT 31 2002

Sir:

TECH CENTER 1600/2900

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Ninth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on July 12, 2001, in connection with the above-captioned application. A copy of each document is also provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

YDS  
12-4-02

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.

Applicants wish to bring the following information to the attention of the Examiner. Applicants are aware of an unpublished report that the RNase H and polymerase activities can be separated and that AMV RT missing 1/3 of the amino end of the native molecule results in an enzyme that lacks RNase H activity but still possesses polymerase activity. However, this report has not been confirmed and is believed to be incorrect.


Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Consideration of this Ninth Supplemental Information Disclosure Statement and making the same of record in the prosecution of the above-identified application is respectfully requested.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond  
Attorney for Applicants  
Registration No. 32,893

Date: Feb 20, 2002

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0942.4330002/RWE/MTT	APPLICATION NO. 09/064,057
	APPLICANT GERARD et al.	
	FILING DATE: April 22, 1998	GROUP: Art Unit 1652

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1						
	AE1						
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

RECEIVED  
OCT 31 2002  
TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL1						Yes No
	AM1						Yes No
	AN1						Yes No
	AO1						Yes No
	AP1						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	25	Freeman-Wittig, M.-J. et al., "Differential Effects of Captan on DNA Polymerase and Ribonuclease H Activity of Avian Myeloblastosis Virus Reverse Transcriptase," <i>Biochemistry</i> 25:3050-3055, American Chemical Society (1986).
AS	25	Moelling, K., "Further Characterization of the Friend Murine Leukemia Virus Reverse Transcriptase - RNase H Complex," <i>J. Virol.</i> 18:418-425, American Society for Microbiology (1976).
AT	1	

EXAMINER	DATE CONSIDERED
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	